1. Home
  2. IROH vs IMUX Comparison

IROH vs IMUX Comparison

Compare IROH & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IROH
  • IMUX
  • Stock Information
  • Founded
  • IROH 2021
  • IMUX 2016
  • Country
  • IROH United States
  • IMUX United States
  • Employees
  • IROH N/A
  • IMUX N/A
  • Industry
  • IROH
  • IMUX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IROH
  • IMUX Health Care
  • Exchange
  • IROH Nasdaq
  • IMUX Nasdaq
  • Market Cap
  • IROH 91.2M
  • IMUX 86.3M
  • IPO Year
  • IROH 2023
  • IMUX N/A
  • Fundamental
  • Price
  • IROH $10.39
  • IMUX $1.00
  • Analyst Decision
  • IROH
  • IMUX Strong Buy
  • Analyst Count
  • IROH 0
  • IMUX 6
  • Target Price
  • IROH N/A
  • IMUX $12.67
  • AVG Volume (30 Days)
  • IROH 30.8K
  • IMUX 923.9K
  • Earning Date
  • IROH 01-01-0001
  • IMUX 02-24-2025
  • Dividend Yield
  • IROH N/A
  • IMUX N/A
  • EPS Growth
  • IROH N/A
  • IMUX N/A
  • EPS
  • IROH 0.20
  • IMUX N/A
  • Revenue
  • IROH N/A
  • IMUX N/A
  • Revenue This Year
  • IROH N/A
  • IMUX N/A
  • Revenue Next Year
  • IROH N/A
  • IMUX N/A
  • P/E Ratio
  • IROH $53.09
  • IMUX N/A
  • Revenue Growth
  • IROH N/A
  • IMUX N/A
  • 52 Week Low
  • IROH $9.97
  • IMUX $0.92
  • 52 Week High
  • IROH $11.11
  • IMUX $2.11
  • Technical
  • Relative Strength Index (RSI)
  • IROH N/A
  • IMUX 50.39
  • Support Level
  • IROH N/A
  • IMUX $0.92
  • Resistance Level
  • IROH N/A
  • IMUX $0.97
  • Average True Range (ATR)
  • IROH 0.00
  • IMUX 0.06
  • MACD
  • IROH 0.00
  • IMUX 0.01
  • Stochastic Oscillator
  • IROH 0.00
  • IMUX 66.61

About IROH Iron Horse Acquisitions Corp. Common Stock

Iron Horse Acquisitions Corp is a blank check company.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: